A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Advanced Gastrointestinal Tumors Clinical Trial

Official title:
A Phase 1/2 Dose Escalation and Expansion Study of Donafenib Tosilate Tablets in Combination With KN046 Injection in Advanced Gastrointestinal Tumors

Status Recruiting

Clinical Trial Summary

This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of Donafenib combined with KN046 in subjects with Advanced Gastrointestinal Tumors.

Clinical Trial Description

The study consists of dose escalation and dose expansion. The preset dose of Donafenib is 50 mg BID, 100 mg BID and 200 mg BID, and the preset dose of KN046 is 5 mg/kg Q3W. Dose expansion will enroll subjects who with advanced hepatocellular carcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04612712
Study type	Interventional
Source	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Contact	Tianshu Liu, PhD
Phone	021-64041990
Email	Liu.tianshu@zs-hospital.sh.cn
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	January 19, 2021
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01916447` - A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.	Phase 1
Not yet recruiting	`NCT03977077` - Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol	N/A
Recruiting	`NCT06197178` - A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)	Phase 1
Completed	`NCT01927965` - Study of Minnelide™ in Patients With Advanced GI Tumors	Phase 1